TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26063354
Drug: Sarpogrelate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarpogrelate (100 mg three times daily for 6 months)
Study: 26063354
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg once daily for 6 months)
Study: 23242806
Drug: traditional prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: traditional prescription approach
Study: 10190919
Drug: Anti-neutrophil cytoplasmic
Normalized name: Anti-neutrophil cytoplasmic antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-neutrophil cytoplasmic antibodies (ANCAs) and anti-Saccharomyces cerevisiae antibodies (ASCA) together
Study: 7000296
Drug: Atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 100 mg once daily + Chlorthalidone 25 mg once daily
Study: 28379536
Drug: Tolvaptan (early
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan (early treatment)
Study: 27111644
Drug: 19-G multiport
Normalized name: MENTHOL 19 g in 100 TOPICAL PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 19-G multiport wire-reinforced catheter
Study: 27111644
Drug: 19-G uniport
Normalized name: MENTHOL 19 g in 100 TOPICAL PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 19-G uniport wire-reinforced catheter
Study: 22295895
Drug: (R,S)‐Ket (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: (R,S)‐Ket (0.5 mg kg⁻¹) infusion for 40 min
Study: 17698683
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (500 mg/d)
Study: 16202900
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream applied to the groin 60 minutes before the procedure
Study: 12362933
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate 3000 mg
Study: 12362933
Drug: Calcium acetate
Normalized name: Calcium Acetate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium acetate 2668 mg
Study: 12362933
Drug: Sevelamer HCl
Normalized name: SEVELAMER HCL
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevelamer HCl 2821 mg
Study: 8833208
Drug: Alendronate 5
Normalized name: ALENDRONATE 5MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 5 mg/day for 3 years
Study: 8833208
Drug: Alendronate 10
Normalized name: ALENDRONATE 10MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 10 mg/day for 3 years
Study: 12669736
Drug: Alendronate 20
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate 20 mg/day for 2 years followed by 5 mg/day for 1 year
Study: 7758493
Drug: Potassium salt
Normalized name: Lactic acid, potassium salt
DrugBank: Potassium lactate (DB09483)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium salt of penicillin V, 50,000 U/kg per day in three divided doses
Study: 7758493
Drug: Benzathine salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzathine salt of penicillin V, 50,000 U/kg per day in two divided doses
Study: 7758493
Drug: Benzathine salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzathine salt of penicillin V, 100,000 U/kg per day in two divided doses
Study: 2265640
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase (within 3 hours)
Study: 2265640
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase (3-6 hours after onset)
Study: 7358942
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg lodoxamide ethyl
Study: 7358942
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg lodoxamide ethyl
Study: 7410746
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg lodoxamide ethyl
Study: 22413944
Drug: CZP 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: CZP 400 mg
Study: 22413944
Drug: CZP 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CZP 200 mg
Study: 28333288
Drug: Vedolizumab induction
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vedolizumab induction therapy
Study: 22793965
Drug: Oral ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ketoprofen 150 mg preemptively administered every 12 hours for two days before surgery
Study: 22793965
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered every 12 hours for two days before surgery
Study: 22793965
Drug: Oral ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ketoprofen 150 mg administered every 12 hours for three days post-surgery
Study: 19117872
Drug: Very early
Normalized name: Primula veris extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very early surfactant therapy with nasal continuous positive airway pressure
Study: 17126951
Drug: 6 min
Normalized name: garlic 6 minim ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 min infusion of vinorelbine
Study: 12413984
Drug: Dexamethasone (DEX)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DEX) combined with clomiphene citrate (CC)
Study: 12413984
Drug: Placebo combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo combined with clomiphene citrate (CC)
Study: 25128004
Drug: Relating therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relating therapy (16 hours, weekly sessions of one hour)
Study: 22946700
Drug: Individualised goal-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised goal-directed therapy targeting stroke volume and oxygen delivery
Study: 16635606
Drug: Statins (atorvastatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statins (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, or simvastatin)
Study: 9093230
Drug: Adjunctive corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive corticosteroid therapy
Study: 2953312
Drug: 0.75% metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% metronidazole gel applied twice daily
Study: 29444376
Drug: Secukinumab 300
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 300 mg (every 4 weeks)
Study: 17486470
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus progesterone therapy (EPT)
Study: 14670288
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy with 8-, 15-, and 20-day induction protocols
Study: 14670288
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving symptomatic treatments
Study: 2061979
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy administered to 733 patients
Study: 2061979
Drug: No thrombolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No thrombolytic therapy (1498 patients)
Study: 24680228
Drug: Immediate individual
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate individual cognitive-behavioral therapy for BDD (CBT-BDD), 22 sessions over 24 weeks
Study: 24680228
Drug: Immediate individual
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate individual cognitive-behavioral therapy for BDD (CBT-BDD)
Study: 15485012
Drug: Lumiracoxib 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumiracoxib 200 mg once daily
Study: 7807693
Drug: Imipenem/cilastatin sodium
Normalized name: imipenem/cilastatin sodium 250 mg INTRAVEN VIAL (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin sodium 1 g/1 g b.i.d.
Study: 7807693
Drug: Imipenem/cilastatin sodium
Normalized name: imipenem/cilastatin sodium 250 mg INTRAVEN VIAL (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin sodium 0.5 g/0.5 g q.i.d.
Study: 3042876
Drug: BS-WC vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: BS-WC vaccine
Study: 2665350
Drug: WC-only vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: WC-only vaccine
Study: 15825396
Drug: Isoprinosine, 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoprinosine, 6 g a day for 2 days prior to challenge and for 7 post-challenge days
Study: 30935260
Drug: Phototherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phototherapy plus Narrowband UVB plus oral silymarin
Study: 31820598
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus auricular therapy group
Study: 31820598
Drug: Auricular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular therapy group
Study: 11715353
Drug: Ramipril 2.5
Normalized name: ramipril 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 2.5 mg/day
Study: 11715353
Drug: Ramipril 10
Normalized name: ramipril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 10 mg/day
Study: 23532746
Drug: MK-8998 12/16
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8998 12/16 mg daily
Study: 23532746
Drug: Olanzapine 10/15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 10/15 mg daily
Study: 21395892
Drug: Crushed buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed buprenorphine (2 mg)
Study: 21395892
Drug: Crushed buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed buprenorphine (8 mg)
Study: 21395892
Drug: Crushed buprenorphine/naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed buprenorphine/naloxone (2/0.5 mg)
Study: 21395892
Drug: Crushed buprenorphine/naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed buprenorphine/naloxone (8/2 mg)
Study: 21395892
Drug: Intravenous buprenorphine/naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous buprenorphine/naloxone (0.8 mg buprenorphine/0.2 mg naloxone)
Study: 21395892
Drug: All intranasal
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All intranasal doses
Study: 10919340
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg enalapril wafer
Study: 10919340
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg enalapril tablet
Study: 28457847
Drug: Mechanical curettage
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical curettage + adjunct antimicrobial photodynamic therapy (MC + aPDT)
Study: 26054138
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of midodrine hydrochloride tablets, 2.5 mg per treatment, three times each day for 4 weeks.
Study: 19506195
Drug: Medication use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication use associated with DED
Study: 15671911
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of vitamin C
Study: 9793662
Drug: Morphine-bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine-bupivacaine
Study: 25813765
Drug: Riociguat (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riociguat (up to 2.5 mg 3 times a day for 16 weeks)
Study: 20400552
Drug: Intensive comparison
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive comparison therapy
Study: 19209016
Drug: Standard antiemetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antiemetic prophylaxis (5-HT3 receptor antagonist and dexamethasone)
Study: 17986903
Drug: Cr-Protein-Carbohydrate (Cr-PRO-CHO)
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cr-Protein-Carbohydrate (Cr-PRO-CHO) supplement (1.5 g x kg(‐1) body weight x d(‐1) and 0.1 g x kg(‐1) body weight x d(‐1) of creatine)
Study: 17986903
Drug: Protein-Carbohydrate (PRO-CHO)
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-Carbohydrate (PRO-CHO) supplement
Study: 17986903
Drug: Protein (PRO)
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein (PRO) supplement
Study: 12040275
Drug: Chemoradiation (radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiation (radiation plus chemotherapy)
Study: 12040275
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy alone (control arm)
Study: 9660430
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized DHEA (25 mg/d)
Study: 2654790
Drug: Cytosine arabinoside
Normalized name: Cytosine arabinoside
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytosine arabinoside (Ara‐C) at high dose (3.0 g/m2)
Study: 2654790
Drug: Cytosine arabinoside
Normalized name: Cytosine arabinoside
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytosine arabinoside (Ara‐C) at intermediate dose (1.0 g/m2)
Study: 2654790
Drug: Cytosine arabinoside
Normalized name: Cytosine arabinoside
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytosine arabinoside (Ara‐C) at low dose (0.5 g/m2)
Study: 319122
Drug: Meptazinol (400-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meptazinol (400-mg capsules)
Study: 24532471
Drug: Speed-feedback therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speed-feedback therapy with a bicycle ergometer (once a week for four weeks)
Study: 17611739
Drug: pergolide (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: pergolide (0.1 mg)
Study: 20446946
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus clopidogrel (dual antiplatelet therapy)
Study: 28554486
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus ticagrelor 90 mg once daily
Study: 28554486
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus ticagrelor 45 mg twice daily
Study: 28554486
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus clopidogrel 75 mg
Study: 28554486
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between low-dose ticagrelor groups (90 mg QD and 45 mg BID)
Study: 28554486
Drug: Ticagrelor 90
Normalized name: ticagrelor 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 90 mg QD
Study: 31930057
Drug: Vortioxetine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine (10 mg/day)
Study: 31990207
Drug: Venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine XR (150 mg/day)
Study: 19345831
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg) with ethambutol placebo
Study: 19345831
Drug: Ethambutol (15-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethambutol (15-20 mg/kg) plus moxifloxacin placebo
Study: 11296057
Drug: Budesonide aqueous
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide aqueous nasal spray, 128 microg once daily in the morning and placebo in the evening
Study: 11296057
Drug: Budesonide aqueous
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide aqueous nasal spray, 128 microg twice daily
Study: 11296057
Drug: Budesonide aqueous
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide aqueous nasal spray, 256 microg once daily in the morning and placebo in the evening
Study: 9245962
Drug: 10 mM
Normalized name: potassium 10 MMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mM mangafodipir trisodium infusion (MnDPDP) administered at doses of 5 and 10 mumol/kg b.w. by bolus injection (< 1 min) to 5 subjects and by infusion (20 min) to 8 subjects.
Study: 3788228
Drug: Cimetidine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (3 X 200 mg plus 1 X 400 mg daily for one week)
Study: 3788228
Drug: Ranitidine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (2 X 150 mg daily for one week)
Study: 31473291
Drug: Drug Holidays
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug Holidays (DH)
Study: 31473291
Drug: Weight Recovery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight Recovery Treatments (WRT) overall
Study: 31473291
Drug: CNS Stimulants
Normalized name: CNS STIMULANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNS Stimulants
Study: 18456528
Drug: Monthly oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly oral ibandronate 150mg
Study: 11081890
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose aprotinin (n = 100)
Study: 11081890
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of aprotinin and epsilon aminocaproic acid (n = 60)
Study: 3096350
Drug: Oral L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral L-carnitine supplementation (60 mumol/kg daily) for seven consecutive days
Study: 3936908
Drug: Oral L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral L-carnitine supplementation
Study: 11919725
Drug: rhIL-11, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL-11, 50 microg/kg subcutaneously daily for up to 21 days
Study: 11252079
Drug: Magnesium oxide
Normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium oxide supplementation (212 mg.d-1)
Study: 9260071
Drug: Alcohol (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (1.0 ml/kg)
Study: 9260071
Drug: Active placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active placebo (0.1 ml/kg)
Study: 29621042
Drug: Ocriplasmin 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocriplasmin 0.125 mg injected once
Study: 26795064
Drug: Frontline Tri-Act(®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frontline Tri-Act(®) topical treatment
Study: 25008392
Drug: Fulranumab 10
Normalized name: Fulranumab
DrugBank: Fulranumab (DB12102)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulranumab 10 mg
Study: 25008392
Drug: Fulranumab (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulranumab (1, 3, or 10 mg)
Study: 19210877
Drug: Iloprost therapy
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost therapy (5-day infusion)
Study: 16164452
Drug: Low-dose, double-blind,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose, double-blind, placebo-controlled food challenge (DBPCFC) with peanut
Study: 8708947
Drug: Chlorhexidine (CHX)
Normalized name: chlorhexidine gluconate Topical Solution [CHX Plus]
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine (CHX) acetate chewing gum (5.0 mg CHX acetate/piece)
Study: 8708947
Drug: Sorbitol-containing chewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbitol-containing chewing gum (1.0 g sorbitol/piece)
Study: 8708947
Drug: Xylitol-containing chewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol-containing chewing gum (0.8 g xylitol/piece)
Study: 23888342
Drug: Testosterone replacement
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone replacement therapy with physiotherapy (TRT+PT) for 6 months
Study: 23888342
Drug: Testosterone replacement
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone replacement therapy alone (TRT) for 6 months
Study: 21482968
Drug: Bivalirudin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin monotherapy (n=1800)
Study: 21482968
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus glycoprotein IIb/IIIa inhibitor (GPI) (n=1802)
Study: 17631392
Drug: etoricoxib 30
Normalized name: Etoricoxib 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: etoricoxib 30 mg q.d.
Study: 17631392
Drug: ibuprofen 2400
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ibuprofen 2400 mg (800 mg t.i.d.)
Study: 11732707
Drug: Ketamine (noncompetitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (noncompetitive NMDA receptor antagonist)
Study: 10874361
Drug: Nimodipine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (120 mg/day for 28 days)
Study: 8580704
Drug: Measurement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measurement of unbound L-tryptophan concentrations using reverse-phase HPLC with fluorescence detection
Study: 31529159
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no adverse events or medication stoppage)
Study: 29168741
Drug: Tyrosine 100
Normalized name: tyrosine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine 100 mg/kg
Study: 29168741
Drug: Tyrosine 200
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tyrosine 200 mg/kg
Study: 29168741
Drug: Tyrosine 150
Normalized name: TYROSINE 150 ug / PANTOTHENIC ACID 15 mg / METHYLCOBALAMIN 1 mg / CHOLECALCIFEROL 1200 [USP'U] / THIAMINE 1 mg / LEVOMEFOLATE CALCIUM 6 mg / RIBOFLAVIN 5'-PHOSPHATE 3 mg / PYRIDOXAL 5-PHOSPHATE 10 mg / NIACINAMIDE 5 mg / ASCORBIC ACID 85 ug ORAL TABLET [Neuro 110]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine 150 mg/kg (young adults)
Study: 21942708
Drug: NOMAC/E2 (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOMAC/E2 (2.5 mg/1.5 mg) in a 24/4-day regimen (n=60)
Study: 21942708
Drug: LNG/EE (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNG/EE (150 μg/30 μg) in a 21/7-day regimen (n=61)
Study: 18046544
Drug: Reboxetine (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine (selective NE reuptake inhibitor)
Study: 18046544
Drug: Nadolol (peripheral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (peripheral beta-adrenergic antagonist)